Intellia Therapeutics Inc
NTLA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.64B
Close$
$0.57
95.1% downside
Current Fair Value
95.1% downsideOvervalued by 95.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.64 Billion |
|---|---|
| Enterprise Value | $1.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.81 |
| Beta | 1.82 |
| Outstanding Shares | 133,480,000 |
Return
| Return on Equity | -54.96% |
|---|---|
| Return on Assets | -46.66% |
| Return on Invested Capital | -25.24% |
Valuation & Multiples
| P/E Ratio | -3.49 |
|---|---|
| PEG | -65.77 |
| Price to Sales | -11.74 |
| Price to Book Ratio | 2.35 |
| Enterprise Value to Revenue | -196.89 |
| Enterprise Value to EBIT | -8.19 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$12.98 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$9.74 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4456▲ 7.13% |
|---|---|
| Total Calls | 2,900,100▼ 26.26% |
| Total Puts | 1,292,300▼ 12.23% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.62%▲ 17.41% |
|---|---|
| Total Invested | $2.61B▲ 84.50% |
| Investors Holding | 354▲ 32.00% |
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...